Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

Author： Cirone Pasquale   Andresen Catharine   Eswaraka Jeetendra   Lappin Patrick   Bagi Cedo  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.73, Iss.3, 2014-03, pp. : 525-538

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

2.1.3. Pan-PI3K/mTOR Inhibition

By  

International Journal of Cancer Research and Prevention, Vol. , Iss. , 2017-01 ,pp. : 77-76

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

By                    

International Journal of Oncology, Vol. 45, Iss. 3, 2014-01 ,pp. : 1027-1035

Spandidos Publications

Access to resources Recommend Favorite

Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model

By                

International Journal of Oncology, Vol. 47, Iss. 1, 2015-01 ,pp. : 377-383

Spandidos Publications

Access to resources Recommend Favorite

The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells

By            

Molecular Medicine Reports, Vol. 5, Iss. 2, 2012-01 ,pp. : 503-508

Spandidos Publications

Access to resources Recommend Favorite

Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 16, Iss. 1, 2016-01 ,pp. : 29-37

Bentham Science Publishers

Access to resources Recommend Favorite